Caregen Co., Ltd. (KOSDAQ: 214370)

Market Cap	901.61B
Revenue (ttm)	77.07B
Net Income (ttm)	33.89B
Shares Out	49.13M
EPS (ttm)	689.57
PE Ratio	26.61
Forward PE	23.39
Dividend	880.00 (5.09%)
Ex-Dividend Date	Jun 27, 2024

Volume	258,287
Open	17,610
Previous Close	17,300
Day's Range	17,280 - 18,090
52-Week Range	14,850 - 44,250
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Caregen

Caregen Co., Ltd., a biotechnology company, researches, develops, and commercializes biomimetic peptides worldwide. The company offers filler products under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names; skin care products under the Dermaheal, PURILUX whitening, Pim-Pim-Paul, and Neovert names; scalp care products under the Renokin and Pelo Baum names; and healthy foods under the proGsterol name. It is also developing medicines for COVID-19 treatment, wet macular degeneration, dry macular degeneration, antivira...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 176
• Stock Exchange: KOSDAQ
• Ticker Symbol: 214370

Financial Performance

In 2023, Caregen's revenue was 79.21 billion, an increase of 14.63% compared to the previous year's 69.10 billion. Earnings were 39.93 billion, an increase of 46.44%.